Aspirin and the risk of colorectal cancer in relation to the expression of 15-hydroxyprostaglandin dehydrogenase (HPGD)

Science Translational Medicine

Volumn 6, Issue 233, 2014, Pages

  Fink, Stephen P ^a   Yamauchi, Mai ^b   Nishihara, Reiko ^b,c   Jung, Seungyoun ^b   Kuchiba, Aya ^b,c   Wu, Kana ^b,c   Cho, Eunyoung ^b,d   Giovannucci, Edward ^b,c   Fuchs, Charles S ^b   Ogino, Shuji ^b,c,e   Markowitz, Sanford D ^a   Chan, Andrew T ^b,f  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d BROWN UNIVERSITY   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

15 HYDROXYPROSTAGLANDIN DEHYDROGENASE; ACETYLSALICYLIC ACID; FOLIC ACID; MESSENGER RNA; MULTIVITAMIN; NONSTEROID ANTIINFLAMMATORY AGENT; 15-HYDROXYPROSTAGLANDIN DEHYDROGENASE;

ADULT; AGED; ALCOHOL CONSUMPTION; ARTICLE; BODY MASS; CANCER RISK; COLON MUCOSA; COLONOSCOPY; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PHYSICAL ACTIVITY; PRIORITY JOURNAL; RISK REDUCTION; SIGMOIDOSCOPY; SMOKING; COLORECTAL NEOPLASMS; DEMOGRAPHY; DRUG EFFECTS; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; INCIDENCE; INTESTINE MUCOSA; METABOLISM; MIDDLE AGED; PATHOLOGY; RISK FACTOR;

ASPIRIN; COLORECTAL NEOPLASMS; DEMOGRAPHY; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; HYDROXYPROSTAGLANDIN DEHYDROGENASES; INCIDENCE; INTESTINAL MUCOSA; MALE; MIDDLE AGED; RISK FACTORS; RNA, MESSENGER;

EID: 84899547782     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3008481     Document Type: Article

References (36)

1. A. T. Chan, E. L. Giovannucci, E. S. Schernhammer, G. A. Colditz, D. J. Hunter, W. C. Willett, C. S. Fuchs, A prospective study of aspirin use and the risk for colorectal adenoma. Ann. Intern. Med. 140, 157-166 (2004).
2. A. T. Chan, E. L. Giovannucci, J. A. Meyerhardt, E. S. Schernhammer, G. C. Curhan, C. S. Fuchs, Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer. JAMA 294, 914-923 (2005).
3. E. Flossmann, P. M. Rothwell; British Doctors Aspirin Trial and the UK-TIA Aspirin Trial, Effect of aspirin on long-term risk of colorectal cancer: Consistent evidence from randomised and observational studies. Lancet 369, 1603-1613 (2007).
4. A. T. Chan, E. L. Giovannucci, J. A. Meyerhardt, E. S. Schernhammer, K. Wu, C. S. Fuchs, Aspirin dose and duration of use and risk of colorectal cancer in men. Gastroenterology 134, 21-28 (2008).
5. P. M. Rothwell, M. Wilson, C. E. Elwin, B. Norrving, A. Algra, C. P. Warlow, T. W. Meade, Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-Year follow-up of five randomised trials. Lancet 376, 1741-1750 (2010).
6. J. Burn, A. M. Gerdes, F. Macrae, J. P. Mecklin, G. Moeslein, S. Olschwang, D. Eccles, D. G. Evans, E. R. Maher, L. Bertario, M. L. Bisgaard, M. G. Dunlop, J. W. Ho, S. V. Hodgson, A. Lindblom, J. Lubinski, P. J. Morrison, V. Murday, R. Ramesar, L. Side, R. J. Scott, H. J. Thomas, H. F. Vasen, G. Barker, G. Crawford, F. Elliott, M. Movahedi, K. Pylvanainen, J. T. Wijnen, R. Fodde, H. T. Lynch, J. C. Mathers, D. T. Bishop; CAPP2 Investigators, Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: An analysis from the CAPP2 randomised controlled trial. Lancet 378, 2081-2087 (2011).
7. W. K. Chia, R. Ali, H. C. Toh, Aspirin as adjuvant therapy for colorectal cancer - Reinterpreting paradigms. Nat. Rev. Clin. Oncol. 9, 561-570 (2012).
8. N. R. Cook, I. M. Lee, S. M. Zhang, M. V. Moorthy, J. E. Buring, Alternate-day, low-dose aspirin and cancer risk: Long-term observational follow-up of a randomized trial. Ann. Intern. Med. 159, 77-85 (2013).
9. B. Pasche, Differential effects of aspirin before and after diagnosis of colorectal cancer. JAMA 309, 2598-2599 (2013).
10. D. Tougeron, D. Sha, S. Manthravadi, F. A. Sinicrope, Aspirin and colorectal cancer: Back to the future. Clin. Cancer Res. 20, 1087-1094 (2014).
11. A. T. Chan, S. Ogino, C. S. Fuchs, Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N. Engl. J. Med. 356, 2131-2142 (2007).
12. S. Kraus, I. Naumov, N. Arber, COX-2 active agents in the chemoprevention of colorectal cancer. Recent Results Cancer Res. 191, 95-103 (2013).
13. R. Nishihara, P. Lochhead, A. Kuchiba, S. Jung, M. Yamauchi, X. Liao, Y. Imamura, Z. R. Qian, T. Morikawa, M. Wang, D. Spiegelman, E. Cho, E. Giovannucci, C. S. Fuchs, A. T. Chan, S. Ogino, Aspirin use and risk of colorectal cancer according to BRAF mutation status. JAMA 309, 2563-2571 (2013).
14. M. Yan, R. M. Rerko, P. Platzer, D. Dawson, J. Willis, M. Tong, E. Lawrence, J. Lutterbaugh, S. Lu, J. K. Willson, G. Luo, J. Hensold, H. H. Tai, K. Wilson, S. D. Markowitz, 15-Hydroxyprostaglandin dehydrogenase, a COX-2 oncogene antagonist, is a TGF-β-induced suppressor of human gastrointestinal cancers. Proc. Natl. Acad. Sci. U.S.A. 101, 17468-17473 (2004).
15. M. G. Backlund, J. R. Mann, V. R. Holla, F. G. Buchanan, H. H. Tai, E. S. Musiek, G. L. Milne, S. Katkuri, R. N. DuBois, 15-Hydroxyprostaglandin dehydrogenase is down-regulated in colorectal cancer. J. Biol. Chem. 280, 3217-3223 (2005).
16. S. J. Myung, R. M. Rerko, M. Yan, P. Platzer, K. Guda, A. Dotson, E. Lawrence, A. J. Dannenberg, A. K. Lovgren, G. Luo, T. P. Pretlow, R. A. Newman, J. Willis, D. Dawson, S. D. Markowitz, 15-Hydroxyprostaglandin dehydrogenase is an in vivo suppressor of colon tumorigenesis. Proc. Natl. Acad. Sci. U.S.A. 103, 12098-12102 (2006).
17. M. Yan, S. J. Myung, S. P. Fink, E. Lawrence, J. Lutterbaugh, P. Yang, X. Zhou, D. Liu, R. M. Rerko, J. Willis, D. Dawson, H. H. Tai, J. S. Barnholtz-Sloan, R. A. Newman, M. M. Bertagnolli, S. D. Markowitz, 15-Hydroxyprostaglandin dehydrogenase inactivation as a mechanism of resistance to celecoxib chemoprevention of colon tumors. Proc. Natl. Acad. Sci. U.S.A. 106, 9409-9413 (2009).
18. 2 by regulating COX-2 and 15-PGDH to promote survival during the microenvironmental stress of glucose deprivation. Carcinogenesis 32, 1741-1747 (2011).
19. C. L. Thompson, S. P. Fink, J. D. Lutterbaugh, R. C. Elston, M. L. Veigl, S. D. Markowitz, L. Li, Genetic variation in 15-hydroxyprostaglandin dehydrogenase and colon cancer susceptibility. PLOS One 8, e64122 (2013).
20. H. J. Lee, D. H. Yang, Y. M. Ryu, M. Song, H. J. Song, K. W. Jung, K. J. Kim, B. D. Ye, J. S. Byeon, E. K. Choi, S. K. Yang, J. H. Kim, S. J. Myung, 15-Hydroxyprostaglandin dehydrogenase in colorectal mucosa as a potential biomarker for predicting colorectal neoplasms. J. Korean Med. Sci. 28, 1154-1160 (2013).
21. R. Benamouzig, B. Uzzan, J. Deyra, A. Martin, B. Girard, J. Little, S. Chaussade; Association pour la Prévention par l'Aspirine du Cancer Colorectal Study Group (APACC), Prevention by daily soluble aspirin of colorectal adenoma recurrence: 4-Year results of the APACC randomised trial. Gut 61, 255-261 (2012).
22. C. Bosetti, V. Rosato, S. Gallus, J. Cuzick, C. La Vecchia, Aspirin and cancer risk: A quantitative review to 2011. Ann. Oncol. 23, 1403-1415 (2012).
23. F. V. Din, A. Valanciute, V. P. Houde, D. Zibrova, K. A. Green, K. Sakamoto, D. R. Alessi, M. G. Dunlop, Aspirin inhibits mTOR signaling, activates AMP-activated protein kinase, and induces autophagy in colorectal cancer cells. Gastroenterology 142, 1504-1515.e1503 (2012).
24. P. M. Rothwell, Aspirin in prevention of sporadic colorectal cancer: Current clinical evidence and overall balance of risks and benefits. Recent Results Cancer Res. 191, 121-142 (2012).
25. P. M. Rothwell, J. F. Price, F. G. Fowkes, A. Zanchetti, M. C. Roncaglioni, G. Tognoni, R. Lee, J. F. Belch, M. Wilson, Z. Mehta, T. W. Meade, Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: Analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet 379, 1602-1612 (2012).
26. P. M. Rothwell, M. Wilson, J. F. Price, J. F. Belch, T. W. Meade, Z. Mehta, Effect of daily aspirin on risk of cancer metastasis: A study of incident cancers during randomised controlled trials. Lancet 379, 1591-1601 (2012).
27. M. J. Thun, E. J. Jacobs, C. Patrono, The role of aspirin in cancer prevention. Nat. Rev. Clin. Oncol. 9, 259-267 (2012).
28. A. T. Chan, N. Arber, J. Burn, W. K. Chia, P. Elwood, M. A. Hull, R. F. Logan, P. M. Rothwell, K. Schrör, J. A. Baron, Aspirin in the chemoprevention of colorectal neoplasia: An overview. Cancer Prev. Res. 5, 164-178 (2012).
29. S. P. Fink, D. H. Yang, J. S. Barnholtz-Sloan, Y. M. Ryu, D. Mikkola, J. D. Potter, J. W. Lampe, S. D. Markowitz, S. J. Myung, Colonic 15-PGDH levels are stable across distance and time and are not perturbed by aspirin intervention. Dig. Dis. Sci. 58, 2615-2622 (2013).
30. T. Morikawa, A. Kuchiba, M. Yamauchi, J. A. Meyerhardt, K. Shima, K. Nosho, A. T. Chan, E. Giovannucci, C. S. Fuchs, S. Ogino, Association of CTNNB1 (β-catenin) alterations, body mass index, and physical activity with survival in patients with colorectal cancer. JAMA 305, 1685-1694 (2011).
31. S. A. Bustin, V. Benes, J. A. Garson, J. Hellemans, J. Huggett, M. Kubista, R. Mueller, T. Nolan, M. W. Pfaffl, G. L. Shipley, J. Vandesompele, C. T. Wittwer, The MIQE guidelines: Minimum information for publication of quantitative real-time PCR experiments. Clin. Chem. 55, 611-622 (2009).
32. M. W. Pfaffl, A. Tichopad, C. Prgomet, T. P. Neuvians, Determination of stable housekeeping genes, differentially regulated target genes and sample integrity: BestKeeper - Excel-based tool using pair-wise correlations. Biotechnol. Lett. 26, 509-515 (2004).
33. C. L. Andersen, J. L. Jensen, T. F. Ørntoft, Normalization of real-time quantitative reverse transcription-PCR data: A model-based variance estimation approach to identify genes suited for normalization, applied to bladder and colon cancer data sets. Cancer Res. 64, 5245-5250 (2004).
34. J. Hellemans, G. Mortier, A. De Paepe, F. Speleman, J. Vandesompele, qBase relative quantification framework and software for management and automated analysis of real-time quantitative PCR data. Genome Biol. 8, R19 (2007).
35. B. E. Ainsworth, W. L. Haskell, A. S. Leon, D. R. Jacobs Jr., H. J. Montoye, J. F. Sallis, R. S. Paffenbarger Jr., Compendium of physical activities: Classification of energy costs of human physical activities. Med. Sci. Sports Exerc. 25, 71-80 (1993).
36. S. Chasan-Taber, E. B. Rimm, M. J. Stampfer, D. Spiegelman, G. A. Colditz, E. Giovannucci, A. Ascherio, W. C. Willett, Reproducibility and validity of a self-administered physical activity questionnaire for male health professionals. Epidemiology 7, 81-86 (1996).